Ann: Cyclopharm Signs First USA Contract for Technegas, page-15

  1. 4,705 Posts.
    lightbulb Created with Sketch. 72
    Bell Potter update snip from yesterday

    "Investment View: Retain Buy, Price Target $4.25
    We conclude that the initial roll out of Technegas in the US is proceeding and expect
    further announcements regarding subsequent contract signings in the short term. We
    have updated the earnings forecast to modestly slow the roll out of Technegas flow
    generators (FGs) as our previous forecast had underestimated the time taken to gain
    Value Analysis Committee Approvals, therefore the company is unlikely to achieve 20
    FG’s by 31 Dec 2023. The forecast now includes updated pricing assumptions and a
    series of minor adjustments. We retain our Buy rating and drop the Speculative risk
    warning. We retain our price target at $4.25."
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
$1.00
Change
0.000(0.00%)
Mkt cap ! $111.1M
Open High Low Value Volume
$1.00 $1.01 99.0¢ $70.22K 70.31K

Buyers (Bids)

No. Vol. Price($)
5 23393 99.0¢
 

Sellers (Offers)

Price($) Vol. No.
$1.00 16508 2
View Market Depth
Last trade - 14.13pm 18/06/2025 (20 minute delay) ?
CYC (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.